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Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we
evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression
of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic
symptoms and experiences using item response bi-factor modelling. Linear regression was used to test the associations between
these dimensions and SZ-PRS, as well as the combined effect of SZ-PRS and cannabis use on the dimensions of positive psychotic
symptoms and experiences. We found associations between SZ-PRS and (1) both negative (B= 0.18; 95%CI 0.03–0.33) and positive
(B= 0.19; 95%CI 0.03–0.35) symptom dimensions in 617 FEP patients, regardless of their categorical diagnosis; and (2) all the
psychotic experience dimensions in 979 controls. We did not observe associations between SZ-PRS and the general and affective
dimensions in FEP. Daily and current cannabis use were associated with the positive dimensions in FEP (B= 0.31; 95%CI 0.11–0.52)
and in controls (B= 0.26; 95%CI 0.06–0.46), over and above SZ-PRS. We provide evidence that genetic liability to schizophrenia and
cannabis use map onto transdiagnostic symptom dimensions, supporting the validity and utility of the dimensional representation
of psychosis. In our sample, genetic liability to schizophrenia correlated with more severe psychosis presentation, and cannabis use
conferred risk to positive symptomatology beyond the genetic risk. Our findings support the hypothesis that psychotic experiences
in the general population have similar genetic substrates as clinical disorders.
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INTRODUCTION
The nosology of psychotic disorders relies on operationalised
criteria. These criteria are based on the type and course of
symptomatology and neglect the currently known risk factors for
psychosis [1]. While the utility of the operationalised approach has
been instrumental in standardising clinical practice and research
internationally, it has also carried nosological limitations [2]. For
example, the clear-cut division of non-affective and affective
psychosis has been unsatisfactory both in clinical practice [3] and
genetic epidemiology; indeed, the latter has consistently shown
that the diagnostic categories of schizophrenia and bipolar
disorder share much of their biological roots [4]. However, due
to the traditional focus on diagnostic categories, questions as to
whether there is a continuity of risk factors across the
transdiagnostic continuum of psychosis have been marginally
investigated. Therefore, an approach based on continuous,
transdiagnostic symptom dimensions across the psychosis spec-
trum might be more appropriate to address this question [5].
Different solutions have been proposed for the structural
modelling of psychopathology, including one or more factors
(i.e. unidimensional and multidimensional solutions) [6]. Recently,
there has been a renewed interest in the bi-factor solution [7, 8],
which suits latent constructs that cannot be fully determined as
unidimensional or multidimensional, as is likely to be the case in
psychosis [9]. The bi-factor model of psychopathology is
composed of a general factor (based on the covariance of all
items) in addition to and independently from multiple specific
symptom factors (based on the covariance of item sub-groups,
e.g. positive, negative, disorganization, manic, and depressive
items) [8, 9]. Each item loading is split between general and
specific factors in a flexible way, to maximise the amount of
variance absorbed by the model [10]. However, this flexibility may
result in a tendency towards data overfitting and abnormal factor
loadings, when compared with correlated multidimensional
solutions without a general factor [10]. Nevertheless, any factor
analysis carries some degree of indeterminacy in representing a
theoretical construct [11], and it is assumed that all models are
wrong in principle but some are useful [10]. Opting for a bi-factor
solution allows to examine multidimensionality whilst retaining an
important single target construct [12], such as the general factor,
which is a useful representation of the common mood-psychosis
spectrum in the field of affective and non-affective psychotic
disorders [6, 9, 10, 13].
Within this methodological framework, we have recently
investigated the relationship between a bi-factor model of
psychopathology at first-episode psychosis (FEP) [14] and
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cannabis consumption [15]. Psychoactive compounds in recrea-
tional cannabis may elicit positive symptoms by interacting with
the endocannabinoid system [16]; moreover, converging evi-
dence suggests that cannabis users who develop psychosis have
less neurodevelopmental impairments than their non-user
counterparts [17]. Supporting this, in a dimensional representa-
tion of psychosis, we see that cannabis users presented at FEP
with more positive and fewer negative symptoms [15], the latter
considered a proxy of early neurodevelopmental impairment in
psychosis [18].
Moreover, in recent years the availability of summary statistics
from large genome-wide association studies (GWAS) across
psychiatric phenotypes has allowed researchers to test within
independent samples how the genetic liability to a disorder
predicts any other traits [19]. This genetic liability can be
summarised into a polygenic risk score (PRS) [19]. However, only
a few studies to date have investigated the relationship between
PRS and transdiagnostic symptom dimensions in psychosis, and
no studies have particularly examined the general factor [20].
Three studies on schizophrenia (SZ) patients suggested that SZ-
PRS correlated with negative or disorganised symptoms [21–23],
which was further reported in the Psychiatric Genomics Con-
sortium’s (PGC) large mega-analyses [24, 25]. However, other
studies have not found the same pattern of associations [26, 27],
and only one study reported that SZ-PRS correlated with positive
symptoms [22]. Interestingly, in the general population, an
association was observed between SZ-PRS and either negative
[28, 29] or positive psychotic experiences [30–32]; however,
negative findings have also been reported [33].
The inconsistency across studies could be explained by
differences in study design, methods, GWAS power, as well as
phenotypic characteristics. For example, only two studies
examined patients at the FEP stage [23, 34], thus, minimising
the confounding effects of antipsychotic drugs on symptoms
and capturing a common comparable time point in the course of
illness. Besides, most studies have not performed a factor
analysis of observed symptoms to measure and validate latent
constructs.
In the present study, we sought to examine the continuity of
the effect of heavy cannabis use and genetic liability to psychotic
disorders across the continuum of psychosis symptoms, including
general and specific dimensions from a multinational sample of
FEP [14] and controls representative of the population at risk [15].
Based on a priori hypotheses, we examined: (1) whether SZ-PRS
was associated with (i) a higher score at the positive and negative
dimensions at FEP; and (ii) a higher score at subclinical psychosis
dimensions in controls; and (2) whether previously reported
association of cannabis use with the positive dimensions [15] held
when taking into account SZ-PRS.
MATERIALS AND METHODS
Sample design and procedures
FEP patients and population controls were recruited as part of the
EUropean network of national schizophrenia networks studying Gene-
Environment Interactions (EU-GEI). FEP patients were identified between
2010 and 2015 across six countries to examine incidence rates of psychotic
disorders and patterns of symptomatology [35]. For examining biological
and environmental risk factors, DNA samples were collected, and an
extensive face-to-face assessment was conducted on 1130 FEP and 1497
controls, broadly representative of the population living in each catchment
area by age, sex and ethnic group. Patients were included in the
case–control study if meeting the following criteria during the recruitment
period: (a) age between 18 and 64 years; (b) presentation with a clinical
diagnosis for an untreated FEP, even if longstanding [International
Statistical Classification of Diseases and Related Health Problems, Tenth
Revision (ICD-10) codes F20–F33]; (c) residency within the catchment area.
Exclusion criteria were: (a) any previous contact with psychiatric services
for psychosis; (b) psychotic symptoms related to physical or neurological
conditions; and (c) transient psychotic symptoms resulting from acute
intoxication (ICD-10: F1x.5).
The recruitment of controls followed a mixture of random and quota
sampling methods, to achieve the best possible representativeness in age,
sex and ethnicity of the population living in each catchment area. The
identification process varied by site and was based on locally available
sampling frames, including for example, postal addresses lists and general
practitioners’ lists from randomly selected surgeries. When these resources
were not fully available, Internet and newspapers advertising were used to
fill quotas. Exclusion criteria for controls were: (a) diagnosis of a psychotic
disorder; (b) ever having been treated for psychosis. All participants
provided informed written consent. Ethical approval was provided from
local research ethics committees in each catchment area: South London
and Maudsley and Institute of Psychiatry Research Ethics Committee;
National Research Ethics Service Committee East of England–East Cam-
bridge; Medisch-Ethische Toetsingscommissie van het Academisch Cen-
trum te Amsterdam; Comité Ético de Investigación Clínica Hospital
Gregorio Marañón; Comité Ético de Investigación Clínica del Hospital
Clinic de Barcelona; Comité Ético de Investigación Clínica del Hospital
Clinic Universitari de Valencia; Comité Ética de la Investigación Clínica del
Principado de Asturias; Comité Ético de Investigación Clínica de Galicia;
Comité Ético de Investigación Clínica del Hospital Virgen de la Luz de
Cuenca; Comité de Protéction des Personnes–CPP Île de France IX;
Comitato Etico Policlinico S Orsola Malpighi; Comitato Etico Azienda
Ospedaleria Universitaria di Verona; Comitato Etico Palermo 1, Azienda
Ospedaliera Policlinico “Paolo Giaccone”; and Research Ethics Committee
of the clinical Hospital of Ribeirão Preto Medical School, University of São
Paulo, Brazil.
Measures
Data on age, sex, and ethnicity were collected using a modified version of
the Medical Research Council Sociodemographic Schedule [36].
The OPerational CRITeria (OPCRIT) system [37, 38] was used to: (1) assess
pre-morbid history and mental state at FEP; and (2) establish a research-
based standardised diagnosis of psychotic disorder. The OPCRIT consists of
a checklist that can be filled using different sources, e.g. case records or
clinical interviews. Investigators’ training and monitoring was organised
centrally on an online platform, which served to: implement and follow
standardised procedures; provide psychopathology training; conduct all-
site inter-rater reliability pre- [39] and post-training; and monitor the inter-
rater reliability annually during the study [40]. All raters were included in
central interrater reliability computations (k= 0.7). An additional post-
training inter-reliability analysis for individual OPCRIT items was conducted
by study country, which is reported in the supplementary material.
Moreover, psychopathology assessment included the use of the
Schedule for Deficit Syndrome (SDS) [41] to evaluate negative symptoms,
which are not extensively covered by the OPCRIT. The Community
Assessment of Psychic Experiences (CAPE) [42] was administered to
population controls to report their positive, negative, and depressive,
psychotic experiences.
A modified version of the Cannabis Experience Questionnaire (CEQEU-GEI)
[43], included in the supplementary material, was used to collect extensive
information on patterns of cannabis use. For the purpose of this study, we
used two dichotomic variables of the questionnaire on current use and
daily use of cannabis: CEQEU-GEI 15.4 (‘Do you currently use cannabis?’ Yes/
no) and CEQEU-GEI 15.9 (‘How often do/did you use cannabis?’ recoded to
daily use= Yes/no).
Dimensions of psychotic symptoms and experiences
Data from OPCRIT and CAPE were analysed using item response
modelling in Mplus, version 7.4, to estimate two separate bi-factor
models of psychopathology, based on the associations among observer
ratings of psychotic symptoms in patients and self-rating of psychotic
experiences in controls (see Supplementary Figs. S1 and S2). This
methodology is described in full in earlier EU-GEI papers on transdiag-
nostic dimensions [14, 15]. Briefly, OPCRIT and CAPE items were
dichotomised as 0 ‘absent’ or 1 ‘present’, and two different bi-factor
models were estimated for patients and controls. As reported in our
previous publications, to ensure enough covariance coverage for item
response modelling, we used the items with a valid frequency of ‘present’
≥10% in our sample, including individuals with ≤20 missing values in the
psychopathology rating. OPCRIT and CAPE data used in the analysis
contained missing values, which we assumed to be missing at random,
allowing for the maximum likelihood estimator to provide unbiased
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estimates. Bi-factor solutions were compared with three competitive
solutions (i.e. unidimensional, multidimensional, hierarchical models of
psychosis) using, as model fit statistics, Log-Likelihood (LL), Akaike
Information Criterion (AIC), Bayesian Information Criterion (BIC), and
Sample-size Adjusted BIC (SABIC), as reported in the Supplementary
Table S1. McDonald’s omega (ω) [44], omega hierarchical (ωH) [44], and
index H [45], were used as reliability and strength indices.
Data from SDS were analysed in Mplus, version 7.4, following the same
above-described procedure. We did not estimate a bi-factor model for SDS
due to the lack of scope of testing a general factor of negative symptoms
in this study. Instead, based on the structure of the negative symptom
construct [46] and previous factor analysis studies on SDS [47], we
estimated a multidimensional model of negative symptoms composed of
the two specific dimensions of 1) ‘avolition’ and 2) (lack of) ‘emotional
expressivity’ (see Supplementary Fig. S3). We considered ‘emotional
expressivity’ as the most genuine phenotypic expression of primary
negative symptoms for subsequent analysis, as ‘avolition’ comprises
withdrawal behaviours that partly overlap with depressive symptoms or
may be secondary to paranoia in a FEP sample. SDS was not administered
in one of the study sites, Verona, which was therefore not included in the
analysis of negative symptoms.
Genotype procedure
The EU-GEI case–control sample was genotyped at the MRC Centre for
Neuropsychiatric Genetics and Genomics in Cardiff (UK) using a custom
Illumina HumanCoreExome-24 BeadChip genotyping array covering
570,038 genetic variants. Imputation was performed in the Michigan
Imputation Server, using the Haplotype Reference Consortium reference
panel, with Eagle software for estimating haplotype phase, and Minimac3
for genotype imputation [48–50]. The imputed best-guess genotype was
used for the present analysis.
Population stratification and polygenic risk score calculation
We performed a two-step procedure to fully account for the multi-ethnic
nature of the sample (reported in full in the supplementary material), by
excluding populations in our sample of very different ancestry from
external European GWAS data. Briefly, as a first step, we defined
individual genetic-based ancestry by merging the EU-GEI sample with
the 1000 Genome Project sample phase 3 [51] and applying k-mean
clustering of ancestry Principal Components (PCs) of the overlapping
single nucleotide polymorphisms (SNPs). As a second step, we identified,
in the EU-GEI sample, finest ancestry clusters of individuals through
iterative pruning of principal component analysis (ipPCA) of SNPs, and
we tested for each cluster whether SZ-PRS discriminated cases from
controls (see Supplementary Fig. S4). For downstream analyses, we,
therefore, merged those population clusters where (1) SZ-PRS had
discriminative value and (2) European ancestry was confirmed after
merging with the 1000 Genome Project sample. In the final sample (see
Supplementary Fig. S5), we removed long-range genome regions with
complex linkage disequilibrium (LD) patterns and constructed main SZ-
PRS (see Supplementary Fig. S6). Specifically, in PRSice [52], individuals’
risk variants were weighted by the log(odds ratio), where the odds ratio
was extracted from summary statistics of the PGC2 SZ mega-analysis
[53], which did not include any EU-GEI sample. Logistic regression was
applied to predict case status from SZ-PRS, after covarying for 10
ancestry PCs, sex, age, and primary diagnosis. To measure the variance
explained by PRS, R2 was used as a measure of the difference in variance
between the full-model versus a model with the covariates alone, at the
Table 1. Sociodemographic and clinical differences between genotyped and not-genotyped individuals.
Case/control sample N= 2627 GWAS—NO GWAS—YES Test statistics
N= 556 N= 2,071
(NFEP= 1130, Ncontrols= 1497) (NFEP= 282, Ncontrols= 274) (NFEP= 856, Ncontrols= 1215)
Case/control status
Case 274 (49.3) 856 (41.3) χ2 (1)= 11.3; p= 0.001
Age
Mean (SD) 32.6 (11.5) 34.3 (12.4) t(2,2642)= 2.9; p < 0.05
Gender
Male 299 (53.8) 1104 (53.3) χ2 (1)= 0.03; p= 0.84
Self-reported Ethnicity
White 374 (67.3) 1520 (73.4) χ2 (5 )= 8.5; p= 0.13
Black 78 (14) 226 (10.9)
Mixed 54 (9.7) 172 (8.3)
Asian 17 (3.1) 51 (2.5)
North African 19 (3.4) 57 (2.7)
Other 14 (2.5) 45 (2.2)
Country
United Kingdom 123 (22.1) 459 (22.2) χ2 (5)= 78.7; p < 0.001
Holland 54 (9.7) 352 (17)
Spain 74 (13.3) 352 (17)
France 71 (12.8) 181 (8.7)
Italy 157 (28.2) 310 (15)
Brazil 77 (13.8) 417 (20.1)
Research Domain Criteria Diagnosis (case only sample)
Bipolar disorder 13 (4.7) 47 (5.5) χ2 (4)= 3.3; p= 0.5
Major depression with psychotic features 18 (5.9) 32 (4)
Schizophrenia 84 (30.7) 306 (35.7)
Schizoaffective disorder 116 (42.3) 318 (37.1)
Unspecified psychosis 48 (17.5) 148 (17.3)
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SNPs p-value threshold (PT)= 0.05 [selected a priori as it maximised the
explained variance in case status in the PGC study [53]].
Relationship between symptom dimensions, polygenic risk
scores, and cannabis use
We tested for associations between SZ-PRS and the scores on transdiag-
nostic dimensions of psychotic symptoms/experiences, separately in FEP
and controls, using linear regression.
Specifically, in FEP, we tested for association between SZ-PRS and
general, positive, negative, disorganization, manic, and depressive
symptom dimensions. In controls, we tested for association between SZ-
PRS and general, positive, negative and depressive psychotic experience
dimensions.
To examine the combined associations of cannabis use and SZ-PRS with
the positive dimensions, we used the pattern of cannabis use previously
associated with the highest level of positive symptoms in our sample
[15, 54], i.e. ‘daily use’ in patients and ‘current use’ in controls. We first
checked for correlation with SZ-PRS, and subsequently, we added the two
cannabis terms to the models. We used the likelihood ratio (LR) test to
compare the model fit before and after adding cannabis use to the model.
Given the high number of outcomes (six dimensions in patients, four in
controls) and predictors (SZ-PRS and cannabis use), we controlled the false
discovery rate using the Benjamini and Hochberg procedure [55],
tolerating a 10% false discovery rate (q= 0.10). Furthermore, as a
sensitivity measure, in PRSice, we tested whether the effect of SZ-PRS on
symptom and psychotic experience dimensions held at other PT thresholds
and ran a permutation analysis to control the familywise error rate further.
The latter analysis was done by repeating the PRSice procedure shuffling
the phenotype 5000 times to obtain an empirical distribution of the p-
value at the best PT.
RESULTS
Genotyped sample, population stratification and PRS
computation
Differences between genotyped and not genotyped individuals in
the EU-GEI case–control sample are summarised in Table 1.
Population stratification findings are presented in full in the
Supplementary material. Based on the case–control discriminative
value of SZ-PRS in each population cluster, we analysed 1596
individuals, including 617 FEP and 979 population controls (see
Supplementary Fig. S5), for whom European ancestry was
confirmed using the 1000 Genome Project sample. The ability of
SZ-PRS to distinguish cases from controls in the main sample is
presented in the supplementary material, showing that at PT=
0.05, SZ-PRS accounted for a Nagelkerke’s R2 of 0.09 (p= 6.9 ×
10−25) (see Supplementary Fig. S6).
Psychotic symptom dimensions by PRS in patients
Findings on symptom dimensions in cases by SZ-PRS at PT= 0.05
are shown in Table 2. As expected in PRS cross-trait predictions
[56], the magnitude of the SNPs effect was small for all the
associations detected. Specifically, SZ-PRS was associated with a
higher score for both the positive (B= 0.19, 95% CI 0.03–0.35; p=
0.019) and negative (B= 0.18, 95% CI 0.03–0.33; p= 0.021)
symptom dimensions. We found no association between SZ-PRS
and either the general factor and depressive and manic symptom
dimensions.
Sensitivity analysis showed that the pattern of associations
between SZ-PRS with both positive and negative symptom
dimensions was consistently observed across all PT and remained
relevant even after permutation analysis (see Supplementary Fig.
S7, showing empirical p-values at the best PT threshold of 0.007
and 0.055 for the positive and negative symptom dimensions,
respectively). The violin plots presented in Fig. 1 illustrate the
distribution of predicted values of SZ-PRS after regression, across
individual quantiles of positive psychotic symptoms in cases.
Psychotic experience dimensions by SZ-PRS in controls
A positive association between SZ-PRS and a higher score at all
the psychotic experience dimensions was observed (Table 3).
Sensitivity analysis showed that the association between SZ-PRS
with positive psychotic experiences was consistent across
different PT and remained relevant after permutation analysis
(see Supplementary Fig. S7, showing an empirical p-value of
0.003). Figure 1 reports the distribution of the predicted values of
SZ-PRS after regression according to individual quantiles of
psychotic experiences in controls.
Positive symptom dimensions by PRS and cannabis use in
patients and controls
Figure 2 shows that daily cannabis use (B= 0.31; 95%CI 0.11–0.52;
p= 0.002) and SZ-PRS (B= 0.22; 95%CI 0.04–0.39; p= 0.014) were
independently associated with the positive symptom dimension
in patients, and this joint model improved fit over a model with
SZ-PRS alone (LR chi2(1)= 6.10, p= 0.01).
Similar results were found for the positive psychotic experience
dimension in controls, with main effects of current use of cannabis
(B= 0.26, 95%CI 0.06– 0.46; p= 0.011) and SZ-PRS (B= 0.13, 95%
CI 0.02–0.25; p= 0.022), showing an improvement of the model fit
(LR chi2(1)= 6.42, p= 0.01).
DISCUSSION
Principal findings
This is the first study to investigate the effects of SZ-PRS and
cannabis use on the psychosis dimensions in a FEP case–control
sample. We found that these two factors, independently from
each other, are associated with more clinical and sub-clinical
positive symptoms in both FEP patients and controls. Moreover,
we found a relationship between SZ-PRS and more clinical and
sub-clinical negative symptoms.
Our findings provide evidence that in both patients and
controls, SZ risk variants and cannabis use map onto the latent
Table 2. Symptom dimension scores by SZ-PRS in cases.
Generala Positivea Negativeb Disorganizationa Maniaa Depressiona
B (95% CI) B (95% CI) B (95% CI) B (95% CI) B (95% CI) B (95% CI)
SZ-PRS 0.04 0.19 0.18 −0.01 0.06 −0.06
(−0.09 to 0.18) (0.03 to 0.35) (0.03 to 0.33) (−0.16 to 0.14) (−0.07 to 0.2) (−0.2 to 0.07)
p= 0.528 p= 0.019*† p= 0.021*† p= 0.928 p= 0.378 p= 0.350
B unstandardised regression coefficient, CI confidence interval.
Covariates in multiple models were sex, age, 10 ancestry PCs, and categorical diagnosis.
Associations nominally significant after permutation analysis are shown in bold.
aSymptom dimension score from OPCRIT factor analysis.
bSymptom dimension score from SDS factor analysis.
*P-values nominally significant after Benjamini–Hochberg procedure,
†Benjamini–Hochberg P-value: 0.042.
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structure of psychopathology, which was built using a statistically
guided approach. This supports the validity and utility of the
symptom dimension approach. Further interpretation of the
clinical application of these findings should take into account
the small magnitude of the detected associations.
Comparison with previous research
Our findings extend previous research on the validity of the
psychosis symptom dimensions by determining their relationship
with genetic factors and cannabis use. Supporting the hypothesis
that symptom presentation is partly a function of SZ genetic
liability, we reported an association between SZ-PRS and both
positive and negative symptom dimensions. This is in line with a
meta-analysis suggesting that different SZ risk loci impact on SZ
clinical heterogeneity, e.g., genes related to immune system might
be overrepresented for negative symptoms, and genes related to
addiction and dopamine-synapses might be overrepresented for
positive symptoms [57].
Familial co-aggregation of negative symptoms was reported in
the Danish adoption study [58], in the Roscommon family study
[59], and suggested in the Maudsley twin series studies [60].
Genome-wide suggestive linkages with an effect on negative
symptoms have also been reported, although without reaching a
significant threshold [61, 62]. GWAS and PRS examinations provide
adequate evidence of a polygenic signal for negative symptoms
[21, 22, 24, 25, 63]. Altogether, these studies indicate that the
negative symptom dimension has substantive heritability, and this
may be partly due to cumulative schizophrenia risk loci. The
disorganization dimension has also been reported as having high
heritability in some studies [60, 64], but we found no evidence of
its association with SZ-PRS in our FEP sample. The prevalence of
disorganization symptoms may differ in FEP and chronic patients.
Furthermore, genetic loci impacting on the disorganization
dimension may be different from those carrying a SZ risk [64],
however, this remains speculative.
Our results on the relationship between SZ-PRS and the positive
symptom dimension are less consistent with previous literature.
Familial co-aggregation of positive symptoms was rarely reported
[65, 66]. However, a previous study observed that, in patients with
bipolar disorder, a higher SZ-PRS correlated with mood-
incongruent positive symptoms [67]. Nevertheless, this was not
confirmed by a meta-analysis of schizophrenia PGC and GPC
samples [25, 68]. Whereas in the current study, the EU-GEI sample
consisted of FEP patients; hence symptomatology rating may have
been less confounded by antipsychotic treatment. On the other
hand, PGC and GPC included chronic schizophrenia samples,
where long-term antipsychotic treatment could attenuate positive
symptoms and worsen negative symptom presentation (i.e.
secondary negative symptoms). Moreover, various environmental
factors may impact at different levels on endocannabinoid and
dopaminergic activity, making it difficult to disentangle the risk
variants contribution to positive symptoms over the course of SZ.
In the current study, we replicated the patterns of associations
between SZ-PRS and psychosis dimensions as seen in cases in the
Fig. 1 Quantiles of psychosis dimensions in the general population and separately in FEP patients by SZ-PRS. The violin plots show the
distribution of SZ-PRS in the EU-GEI sample by individuals classified according to their score at the positive experience and symptom
dimensions, separately in population controls (left side) and FEP patients (right side) at different quantiles (0–25% psychotic experiences or
symptoms; 25–75% psychotic experiences or symptoms; 75–100% psychotic experiences or symptoms). Explanatory note: Interquartile range,
95% confidence interval, median and mean are illustrated within the bars. The shape on each side of the bars represents the density
distribution. Dots indicate current cannabis use in controls and daily cannabis use in patients (red= no; green= yes).
Table 3. Psychotic experience dimension scores by SZ-PRS in controls.
Generala Positivea Negativea Depressiona
B (95% CI) B (95% CI) B (95% CI) B (95% CI)
SZ-
PRS
0.19 0.14 0.18 0.15
(0.02 to 0.24) (0.03 to 0.26) (0.05 to 0.3) (0.03 to 0.27)
p= 0.003*†† p= 0.023*† p= 0.005*†† p= 0.012*†
B Unstandardised regression coefficient, CI confidence interval.
Covariates in multiple models were sex, age, and ten ancestry PCs.
Associations nominally significant after permutation analysis are shown
in bold.
aPsychotic experience dimension scores from CAPE factor analysis.
*P-values nominally significant after Benjamini–Hochberg procedure.
†Benjamini–Hochberg P-value: 0.042.
††Benjamini–Hochberg P-value: 0.027.
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control sample, in the form of sub-clinical psychosis. Our findings
support previous evidence that SZ-PRS correlates with psychotic
experiences that in adults may be reflecting similarities with
biological SZ risk factors [31]. This is in line with the theory that
psychosis is distributed as a continuum [69].
Interestingly, the general factor correlated well with the SZ
genetic liability in controls but not in patients. These findings are
in line with the view that psychosis exists on a continuum and
general psychotic experiences though not fully shaped can be
experienced by general population [70]. This is further in support
of a general psychosis factor being a useful and valid phenotype
in the general population [71, 72]. However, it must be acknowl-
edged that the general factor may vary in its structure and
interpretation [73], and the negative finding in cases may be
explained by this factor not exactly reflecting the full range of
general psychopathology in our FEP sample, as we have
previously reported [14].
Furthermore, while we found the most severe level of positive
symptoms at FEP among cannabis users with a high SZ-PRS, our
data clarify that cannabis use is associated with more positive
symptomatology [15, 54, 74] independently of genetic risk. This is
especially important as the phytocannabinoids, contained in
cannabis, exert their psychoactive effects acting on the endocan-
nabinoid system, which is in turn influenced by many other
biological pathways [75]. Moreover, our group has previously
shown that exposure to cannabis accounts for a substantial
proportion of new cases of psychosis across Europe [43]. Present
findings further suggest, in a transdiagnostic fashion, that
exposure to cannabis is associated with experiencing more
psychotic symptoms at FEP independently from the genetic
liability to SZ and regardless of being a case or a control. While
only a small proportion of cannabis users develop a full-blown
psychotic disorder, our results indicate that cannabis use plays an
independent role from SZ genetic liability in shaping psycho-
pathology at psychosis onset.
Limitations
Our findings should be considered in the context of the following
limitations.
(1) We performed extensive work for defining the fine-scale
population structure in a multi-ethnic sample. Indeed,
having a sample of individuals from a single homogenous
population might have improved the quality of the analysis.
However, our study has the advantage of being more
representative of real clinical practice. Most important, we
included as far as possible population clusters not located in
Europe but still suitable for PRS analyses, which is in line
with the ethical aim of trying to not contribute to health
disparities [76].
(2) Regarding symptom ratings in patients, we used symptom
dimensions from two different scales, i.e., negative from
SDS, and the other symptom dimensions from OPCRIT. In
the EU-GEI study, negative symptoms were accurately rated
through the administration of SDS; moreover, exploratory
factor analyses of OPCRIT in other samples showed that a
hybrid disorganised/negative dimension was often obtained
rather than discrete negative and disorganised dimensions
[25, 77]. Of note, our preliminary analysis of SZ-PRS and
negative dimension using OPCRIT showed no nominal
association [78], due, possibly, to the scarce item covariance
coverage, acknowledged as a limitation in our earlier paper
on symptom dimensions [14].
(3) Regarding the bi-factor solutions, the general factor may be
difficult to interpret and possibly overfits the data [79].
Based on the strength of item factor loadings in our sample,
the general factor could be interpreted: (1) in patients, as
combined manic-delusional symptomatology [14]; (2) in
controls, as a composite measure of all types of psychotic
experiences [15, 54]. Moreover, in our model, the general
factor may improve the measurement of specific
Fig. 2 Positive symptom dimension by SZ-PRS and cannabis use in FEP patients. The graph on the left illustrates the independent and joint
effect of daily cannabis use (blue line: no; red line: yes) and SZ-PRS (x axys) on the positive symptom dimension (y axys). The two graphs on
the right present the main effect of SZ-PRS (in blue, x axys) and daily cannabis use (in red, x axys) on the positive symptom dimension (y axys).
Values are adjusted for age, sex, and 10 ancestry PCs.
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dimensions by making their score not unduly affected by all-
item covariance [14].
(4) We did not validate self-reported information on the current
use of cannabis with biological samples. However, this
method does not allow ascertaining lifetime patterns of
cannabis use [43] and is not considered a gold standard
methodology [80]. Moreover, it has been shown that self-
report information on cannabis use is consistent with
laboratory data [81].
(5) We did not use a PRS based on GWAS of symptom
dimensions, as this is currently unavailable. It is noteworthy
that, genes conferring risk to a disorder (‘risk genes’) may
not overlap with genes modifying symptom presentation
(‘modifier genes’) [82], although it is hypothesised that there
are genes with a mixed effect [57]. Thus, our study answers
the question whether the genetic liability for SZ due to
common variants explains variance of some phenotypic
traits, without accounting for other possible genetic sources
of that variance (i.e. the contribution of modifier genes, copy
number variants, and rare variants).
(6) Finally, SZ-PRS could increase the risk for positive symptoms
in cases and psychosis experiences in controls, without
there being a unique continuous dimension of symptoms
between the two groups. However, we could not examine
cases and controls together, as two different scales were
administered for psychosis rating.
Implications
Clinicians and researchers continue to debate the validity of
psychiatric nosology. We provide evidence that the bi-factor
model of psychopathology is a valid instrument toward conduct-
ing high-quality transdiagnostic research into psychosis. Although
PRSs are not yet applicable in clinical practice, they may serve to
validate theoretical constructs. Furthermore, these findings
reinforce the case for using symptom dimension ratings into
routine clinical practice, which may integrate our traditional
diagnostic categories. They also inform that the risk of experien-
cing positive psychotic symptoms associated with cannabis use is
independent from individual genetic susceptibility to schizophre-
nia. Finally, acknowledging the impact of cannabis use, especially
daily use, on symptoms presentation at first onset psychosis can
guide the development of tailored intervention for those patients
who continue to use cannabis following their illness onset.
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